Focus Partners Wealth
KPTI icon

Focus Partners Wealth’s Karyopharm Therapeutics KPTI Stock Holding History

Focus Partners Wealth’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,055
Closed -$31K – 1986
2024
Q4 		$31K Buy
+3,055
New +$36.9K ﹤0.01% 1836
2024
Q3 		– Sell
-3,062
Closed -$44K – 1654
2024
Q2 		$44K Hold
3,062
– – ﹤0.01% 1203
2024
Q1 		$50K Buy
+3,062
New +$53.7K ﹤0.01% 971

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Focus Partners Wealth's KPTI Position: Q1 2025 in Review

Focus Partners Wealth sold out of Karyopharm Therapeutics (KPTI) in Q1 2025, closing a stake of 3,055 shares — an estimated $31K sold.

Focus Partners Wealth first reported a position in KPTI in Q1 2024 and held it in 3 quarters. The position peaked at $50K in Q1 2024. 49 funds tracked by Wall St. Rank hold KPTI as of Q1 2025.

  • Focus Partners Wealth reported no remaining Karyopharm Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Focus Partners Wealth sold 3,055 Karyopharm Therapeutics shares in Q1 2025, an estimated $31K.
  • Focus Partners Wealth first reported a position in Karyopharm Therapeutics in Q1 2024 and held it in 3 quarters.
  • Focus Partners Wealth's Karyopharm Therapeutics position peaked at $50K in Q1 2024.
  • 49 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2025.

Based on Focus Partners Wealth's 13F filing for Q1 2025, filed 15 May 2025.